Exploring the thiazole scaffold for the identification of new agents for the treatment of fluconazole resistant Candida

References

• Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. J Clin Epidemiol 2011;3:175–91
   PubMedGoogle Scholar
• Mulu A, Kassu A, Anagaw B, et al. Frequent detection of ‘azole' resistant Candida species among late presenting AIDS patients in northwest Ethiopia. BMC Infect Dis 2013;13:82
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010;48:1366–77
   PubMed Web of Science ®Google Scholar
• Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996;9:499–511
   PubMed Web of Science ®Google Scholar
• Roemer T, Krysan DJ. Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med 2014;4:a019703
   PubMed Web of Science ®Google Scholar
• Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308–29
   PubMedGoogle Scholar
• Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12:40–79
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandins: a new class of antifungal. J Antimicrob Chemother 2002;49:889–91
   PubMed Web of Science ®Google Scholar
• Lignell A, Löwdin E, Cars O, et al. Voriconazole-induced inhibition of the fungicidal activity of amphotericin B in Candida strains with reduced susceptibility to voriconazole: an effect not predicted by the MIC value alone. Antimicrob Agents Chemother 2011;55:1629–37
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Dzajic E, Jensen RH, et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013;19:e343–53
   PubMed Web of Science ®Google Scholar
• Lupetti A, Danesi R, Campa M, et al. Molecular basis of resistance to azole antifungals. Trends Mol Med 2002;8:76–81
   PubMed Web of Science ®Google Scholar
• Marchetti O, Moreillon P, Entenza JM, et al. Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1, and FLU1 genes. Antimicrob Agents Chemother 2003;47:1565–70
   PubMed Web of Science ®Google Scholar
• Tragiannidis A, Tsoulas C, Kerl K, Groll AH. Invasive candidiasis: update on current pharmacotherapy options and future perspectives. Expert Opin Pharmacother 2013;14:1515–28
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Hoban DJ, Zhanel GG, Goldstein BP. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Int J Antimicrob Agents 2006;27:174–7
   PubMed Web of Science ®Google Scholar
• Chaturvedi V, Ramani R, Andes D, et al. Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. Antimicrob Agents Chemother 2011;55:1543–8
   PubMed Web of Science ®Google Scholar
• Aperis G, Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Invest Drugs 2006;15:579–602
   PubMed Web of Science ®Google Scholar
• Monk BC, Tomasiak TM, Keniya MV, et al. Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer. Proc Natl Acad Sci U S A 2014;111:3865–70
   PubMed Web of Science ®Google Scholar
• Holbein BE, Mira de Orduña R. Effect of trace iron levels and iron withdrawal by chelation on the growth of Candida albicans and Candida vini. FEMS Microbiol Lett 2010;307:19–24
   PubMed Web of Science ®Google Scholar
• Santos ALS, Sodre CL, Valle RS, et al. Antimicrobial action of chelating agents: repercussions on the microorganism development, virulence and pathogenesis. Curr Med Chem 2012;19:2715–37
   PubMed Web of Science ®Google Scholar
• Opletalová V, Kalinowski DS, Vejsová M, et al. Identification and characterization of thiosemicarbazones with antifungal and antitumor effects: cellular iron chelation mediating cytotoxic activity. Chem Res Toxicol 2008;21:1878–89
   PubMed Web of Science ®Google Scholar
• De Logu A, Saddi M, Cardia MC, et al. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans. J Antimicrob Chemother 2005;55:692–8
   Web of Science ®Google Scholar
• Cardia MC, Begala M, Delogu A, et al. Synthesis and antimicrobial activity of novel arylideneisothiosemicarbazones. Farmaco 2000;55:93–8
   PubMedGoogle Scholar
• Maccioni E, Cardia MC, Bonsignore L, et al. Synthesis and anti-microbial activity of isothiosemicarbazones and cyclic analogues. Farmaco 2002;57:809–17
   PubMedGoogle Scholar
• Chimenti F, Bizzarri B, Maccioni E, et al. Synthesis and in vitro activity of 2-thiazolylhydrazone derivatives compared with the activity of clotrimazole against clinical isolates of Candida spp. Bioorg Med Chem Lett 2007;17:4635–40
   PubMed Web of Science ®Google Scholar
• Chimenti F, Maccioni E, Secci D, et al. Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones. J Med Chem 2008;51:4874–80
   PubMed Web of Science ®Google Scholar
• Chimenti F, Secci D, Bolasco A, et al. Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem 2010;18:5063–70
   PubMed Web of Science ®Google Scholar